2026-04-29T04:09:56Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/187392024-02-27T15:10:17Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Björnsson, Einar S author Stephens, Camilla author Atallah, Edmond author Robles-Diaz, Mercedes author Alvarez-Alvarez, Ismael author Gerbes, Alexander author Weber, Sabine author Stirnimann, Guido author Kullak-Ublick, Gerd author Cortez-Pinto, Helena author Grove, Jane I author Lucena, M Isabel author Andrade, Raul J author Aithal, Guruprasad P author 2022-08-15 No multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported. Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016-2021. DILI cases or non-DILI acute liver injury controls following causality assessment were enrolled. Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis (n = 42) and viral hepatitis (n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre-existing liver disease. DILI cases and non-DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin-clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug-induced autoimmune-like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver-related death), and another six received liver transplantation. In this first multi-national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI. http://hdl.handle.net/10668/20009 http://hdl.handle.net/20.500.12105/18739 35899490 10.1111/liv.15378 1478-3231 Liver international : official journal of the International Association for the Study of the Liver drug aetiologies drug-induced autoimmune-like hepatitis drug-induced liver injury outcomes prospective study A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.